SUMOylation is required for optimal TRAF3 signaling capacity

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Miliara, Sophia ^a,b   Gkouskou, Kalliopi K ^a,b   Sharp, Tyson V ^c   Eliopoulos, Aristides G ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS, CD40; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA; NF-KAPPA B P52 SUBUNIT; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEOLYSIS; SIGNAL TRANSDUCTION; SUMOYLATION; TNF RECEPTOR-ASSOCIATED FACTOR 3; TWO-HYBRID SYSTEM TECHNIQUES; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84894174347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080470     Document Type: Article

References (42)

1. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, et al. (1995) Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 267: 1494-1498.
2. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, et al. (1995) The Epstein-Barr Virus Transforming Protein LMP-1 engages signaling proteins for the Tumour Necrosis Factor Receptor Family. Cell 80: 389-399.
3. Hu HM, O'Rourke K, Boguski MS, Dixit VM (1994) A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 269: 30069-30072. (Pubitemid 24376462)
4. Eliopoulos AG, Young LS (2001) LMP1 structure and signal transduction. Semin Cancer Biol 11: 435-444. (Pubitemid 33105022)
5. Arch RH, Thompson CB (1998) 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 18: 558-565. (Pubitemid 28021066)
6. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, et al. (1998) CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem 273: 13353-13358. (Pubitemid 28246911)
7. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, et al. (1997) Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 272: 2042-2045. (Pubitemid 27058475)
8. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, et al. (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204-207. (Pubitemid 43083141)
9. He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, et al. (2006) Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med 203: 2413-2418. (Pubitemid 44664610)
10. Perez de Diego R, Sancho-Shimizu V, Lorenzo L, Puel A, Plancoulaine S, et al. (2010) Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33: 400-411.
11. Sancho-Shimizu V, Perez de Diego R, Lorenzo L, Halwani R, Alangari A, et al. (2011) Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 121: 4889-4902.
12. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144. (Pubitemid 47208626)
13. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130. (Pubitemid 47199123)
14. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, et al. (1996) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13: 2243-2254. (Pubitemid 26411575)
15. VanArsdale TL, VanArsdale SL, Force WR, Walter BN, Mosialos G, et al. (1997) Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci U S A 94: 2460-2465. (Pubitemid 27136897)
16. Gardam S, Sierro F, Basten A, Mackay F, Brink R (2008) TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28: 391-401.
17. Liao G, Zhang M, Harhaj EW, Sun SC (2004) Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279: 26243-26250. (Pubitemid 38798772)
18. Perez de Diego R, Sancho-Shimizu V, Lorenzo L, Puel A, Plancoulaine S, et al. (2010) Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33: 400-411.
19. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, et al. (2002) CD40 regulates the processing of NF-kappaB2 p100 to p52. Embo J 21: 5375-5385. (Pubitemid 35231017)
20. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, et al. (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9: 1364-1370.
21. Tatham MH, Rodriguez MS, Xirodimas DP, Hay RT (2009) Detection of protein SUMOylation in vivo. Nat Protoc 4: 1363-1371.
22. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY (2010) Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29: 1763-1772.
23. Davies CC, Mak TW, Young LS, Eliopoulos AG (2005) TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol Cell Biol 25: 9806-9819. (Pubitemid 41572731)
24. Gyuris J, Golemis E, Chertkov H, Brent R (1993) Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75: 791-803. (Pubitemid 23346376)
25. Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH (2003) SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem 278: 31043-31048. (Pubitemid 36994618)
26. Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA (2003) Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 278: 45382-45390. (Pubitemid 37432675)
27. Brown KD, Hostager BS, Bishop GA (2001) Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 193: 943-954. (Pubitemid 32525867)
28. Stamenkovic I, Clark EA, Seed B (1989) A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. Embo J 8: 1403-1410. (Pubitemid 19274364)
29. Knox PG, Davies CC, Ioannou M, Eliopoulos AG (2011) The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas. J Cell Biol 192: 391-399.
30. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, et al. (2000) Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha -, CD40-, and epstein-barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 275: 18022-18028.
31. Stewart R, Wei W, Challa A, Armitage RJ, Arrand JR, et al. (2007) CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt's lymphoma cells. J Immunol 179: 2705-2712.
32. van Eyndhoven WG, Frank D, Kalachikov S, Cleary AM, Hong DI, et al. (1998) A single gene for human TRAF-3 at chromosome 14q32.3 encodes a variety of mRNA species by alternative polyadenylation, mRNA splicing and transcription initiation. Mol Immunol 35: 1189-1206. (Pubitemid 29151780)
33. Muller S, Hoege C, Pyrowolakis G, Jentsch S (2001) SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2: 202-210. (Pubitemid 33675745)
34. Ulrich HD (2008) The fast-growing business of SUMO chains. Mol Cell 32: 301-305.
35. Schimmel J, Larsen KM, Matic I, van Hagen M, Cox J, et al. (2008) The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol Cell Proteomics 7: 2107-2122.
36. Geoffroy MC, Hay RT (2009) An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 10: 564-568.
37. Praefcke GJ, Hofmann K, Dohmen RJ (2012) SUMO playing tag with ubiquitin. Trends Biochem Sci 37: 23-31.
38. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555. (Pubitemid 351627374)
39. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 538-546. (Pubitemid 351627373)
40. Widagdo J, Taylor KM, Gunning PW, Hardeman EC, Palmer SJ (2012) SUMOylation of GTF2IRD1 regulates protein partner interactions and ubiquitin-mediated degradation. PLoS One 7: e49283.
41. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, et al. (2008) Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321: 663-668.
42. Loskog AS, Eliopoulos AG (2009) The Janus faces of CD40 in cancer. Semin Immunol. 21(5):301-7.